| Literature DB >> 21111484 |
Virginie Lollier1, Sandra Denery-Papini, Colette Larré, Dominique Tessier.
Abstract
Methods that predict antibody epitopes could help to promote the development of diagnostic tools, vaccines or immunotherapies by affecting the epitope binding of antibodies during an immunological response to antigens. It is generally assumed that there is a direct relationship between antibody accessibility to antigens and accessible surface of proteins. Based on this assumption, prediction systems often includes solvent accessibility values calculated from the primary sequence of proteins or from their three dimensional structures as a predictive criterion. However, the current prediction systems seem weakly efficient in view of benchmark tests. We were interested in evaluating how amino acids that have been experimentally identified as epitopic elements could differ from the rest of the antigenic molecule at the level of surface exposure, hence we assessed the average accessibility of epitopes. The approach used here utilises published epitopes deduced from numerous identification techniques, including sequence scanning and structure visualisation after crystallography, and it involves many types of antigens from toxins to allergens. Our results show that epitopic residues are not distributed among any specific Relative Surface Accessibility and Protrusion Index values and that, in some cases, epitopes cover the entire antigenic sequence. These results led to the conclusion that the classification of known epitopes with respect to the experimental conditions used to identify them should be introduced before attempting to characterise epitopic areas in a generic way.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21111484 PMCID: PMC7112657 DOI: 10.1016/j.molimm.2010.10.011
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407
List of PDB identifiers and their corresponding molecule name.
| PDB ID | Compound name | Experimental data type | Number of epitope sequences | Number of references |
|---|---|---|---|---|
| MITE ALLERGEN DER P 2 | Solution NMR | 15 | 9 | |
| ANTHRAX PROTECTIVE ANTIGEN | X-ray diffraction | 4 | 4 | |
| PRION PROTEIN DOMAIN PRP (121–231) | Solution NMR | 32 | 12 | |
| BOVINE LIPOCALIN ALLERGEN BOS D 2 | X-ray diffraction | 1 | 1 | |
| BAND 3 ANION TRANSPORT PROTEIN | Solution NMR | 2 | 1 | |
| BIRCH POLLEN ALLERGEN BET V 1 | X-ray diffraction | 1 | 1 | |
| PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 1 | Solution NMR | 12 | 6 | |
| BIRCH POLLEN PROFILIN | X-ray diffraction | 1 | 1 | |
| EPIDERMAL GROWTH FACTOR RECEPTOR | Theoretical model | 1 | 1 | |
| L1 PROTEIN OF HUMAN PAPILLOMAVIRUS 16 | X-ray diffraction | 2 | 1 | |
| ERYTHROCRUORIN (CARBONMONOXY) | X-ray diffraction | 10 | 2 | |
| MINI-PROINSULIN | Solution NMR | 4 | 2 | |
| MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85B | X-ray diffraction | 11 | 1 | |
| BEE VENOM HYALUROGLUCOSAMINIDASE ALLERGEN | X-ray diffraction | 1 | 1 | |
| PRION PROTEIN | Solution NMR | 17 | 6 | |
| HEMAGGLUTININ PRECURSOR OF INFLUENZA VIRUS | X-ray diffraction | 8 | 7 | |
| HEVEIN ALLERGEN | Solution NMR | 19 | 5 | |
| ANTHRAX CALMODULIN-SENSITIVE ADENYLATE CYCLASE | X-ray diffraction | 1 | 1 | |
| ALLERGEN JUN A 3 | Theoretical model | 6 | 1 | |
| P. FALCIPARUM HISTIDINE-RICH PROTEIN III | Theoretical model | 1 | 1 | |
| NAJA NIGRICOLLIS VENOM TOXIN ALPHA | Solution NMR | 4 | 3 | |
| EXTERIOR MEMBRANE GLYCOPROTEIN (GP120) OF HIV-1 | Solution NMR | 1 | 1 | |
| BORRELIA BURGDOFERI OUTER SURFACE PROTEIN B | X-ray diffraction | 4 | 4 | |
| MYCOBACTERIUM TUBERCULOSIS 10 KDA CHAPERONIN | Solution NMR | 6 | 3 | |
| BEE-VENOM PHOSPHOLIPASE A2 ALLERGEN | X-ray diffraction | 1 | 1 | |
| AUTOANTIGEN MYELIN-OLIGODENDROCYTE GLYCOPROTEIN | X-ray diffraction | 1 | 1 | |
| SARS CORONAVIRUS E2 GLYCOPROTEIN | Theoretical model | 32 | 12 | |
| HUMAN MYELIN BASIC PROTEIN | Theoretical model | 1 | 1 | |
| YERSINIA PESTIS VIRULENCE-ASSOCIATED V ANTIGEN | X-ray diffraction | 18 | 2 | |
| BOTULINUM NEUROTOXIN TYPE B | X-ray diffraction | 35 | 2 | |
| STAPHYLOCOCCAL ENTEROTOXIN A | Theoretical model | 14 | 5 | |
| MONGOLIAN SNAKE-GOURD TRICHOSANTHIN | X-ray diffraction | 1 | 1 | |
| DENGUE VIRUS ENVELOPE GLYCOPROTEIN | X-ray diffraction | 4 | 1 | |
| GLUTATHIONE S-TRANSFERASE FROM SCHISTOSOMA MANSONI | X-ray diffraction | 9 | 6 | |
| AMYLOID BETA A4 PROTEIN | Theoretical model | 40 | 30 | |
| MITE GROUP 2 ALLERGEN DER F 2 | Solution NMR | 4 | 2 | |
| MAJOR MITE FECAL ALLERGEN DER P 1 | X-ray diffraction | 9 | 3 | |
| MAJOR PRION PROTEIN | Solution NMR | 30 | 11 | |
| MAJOR PRION PROTEIN | Solution NMR | 9 | 5 | |
| B. ANTHRAX LETHAL FACTOR | X-ray diffraction | 41 | 2 | |
| HEPATITIS C VIRUS RNA-DEPENDANT RNA POLYMERASE | X-ray diffraction | 10 | 1 | |
| CIRCUMSPOROZOITE PROTEIN | Theoretical model | 1 | 1 | |
| TSR DOMAIN OF MALARIA TRAP PROTEIN | Solution NMR | 2 | 1 | |
| HEPATITIS C VIRUS RNA-DIRECTED RNA POLYMERASE | X-ray diffraction | 167 | 2 | |
| BORRELIA OUTER SURFACE PROTEIN A | X-ray diffraction | 6 | 4 | |
| MYCOBACTERIUM TUBERCULOSIS IMMUNOGENIC PROTEIN | Solution NMR | 4 | 1 | |
| MITE ALLERGEN BLO T 5 | Solution NMR | 17 | 3 | |
| SARS CORONAVIRUS NUCLEOCAPSID PROTEIN | X-ray diffraction | 3 | 3 | |
| GLUTAMIC ACID DECARBOXYLASE [GAD65) AUTOANTIGEN | X-ray diffraction | 5 | 3 | |
| HEAT-LABILE ENTEROTOXIN B CHAIN | X-ray diffraction | 1 | 1 | |
| STAPHYLOKINASE | X-ray diffraction | 3 | 2 | |
| STAPHYLOCOCCAL THERMONUCLEASE PRECURSOR | X-ray diffraction | 1 | 1 | |
| RICIN TOXIN A CHAIN | X-ray diffraction | 7 | 2 | |
| BOTULINUM NEUROTOXIN HEAVY CHAIN | X-ray diffraction | 33 | 5 | |
| BETA-2-MICROGLOBULIN | X-ray diffraction | 3 | 2 | |
| HEMAGGLUTININ PROTEIN | X-ray diffraction | 38 | 3 | |
| BETA-LACTOGLOBULIN ALLERGEN | X-ray diffraction | 27 | 11 | |
| STAPHYLOCOCCAL ENTEROTOXIN B | X-ray diffraction | 3 | 3 | |
| TOXIC SHOCK SYNDROME TOXIN-1 | X-ray diffraction | 3 | 3 | |
| HEN EGG WHITE LYSOZYME | X-ray diffraction | 2 | 2 |
Fig. 1Treemaps of the relationship between the amino acid accessibility values and their presence within epitopes considering the epitope type (continuous, discontinuous) and the calculation mode (RSA, PI). The treemap consists of a square, which is divided first into horizontal bars whose widths are proportional to the number of amino acids whether or not they have been described within epitopes. Each bar is then split vertically according to the amino acid values for accessibility.
Fig. 2Distribution of RSA (a) and PI (b) of amino acids along the protein sequences where continuous epitopes have been identified (blue spot indicates an epitopic residue).
Fig. 3Distribution of RSA (a) and PI (b) of amino acids along the protein sequences where discontinuous epitopes have been identified (blue spot indicates an epitopic residue).
Fig. 4Number of epitope identification references related to each amino acid along the protein sequences (black line) and their mean protrusion index (grey line).